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a b s t r a c t
A series of 5-androst-3-enes and 3,4-epoxy-5-androstaneswere synthesized and tested
for their abilities to inhibit aromatase in human placental microsomes. In these series the
original C-17 carbonyl group was replaced by hydroxyl, acetyl and hydroxyimine groups.
Inhibition kinetic analysis on the most potent steroid of these series revealed that it inhibits
the enzyme in a competitive manner (IC50 = 6.5M). The achieved data pointed out the
importance of the C-17 carbonyl group in the D-ring of the studied steroids as a struc-eywords:
romatase inhibitor
ynthetic androstanes
tructure–function study
tural feature required to reach maximum aromatase inhibitory activity. Further, at least one
carbonyl group (C-3 or C-17) seems to be essential to effective aromatase inhibition.
© 2008 Elsevier Inc. All rights reserved.
as exemestane and formestane (Fig. 1), mimic the naturalreast cancer
. Introduction
ormone-dependent breast tumors require estrogens for their
rowth [1]. Two main approaches have been applied to block
strogen action. One acts directly at the estrogen receptor, by
eans of selective estrogen receptor modulators (SERMs) and
ther targets aromatase, a cytochrome P-450 enzyme (CYP19),
esponsible for estrogen biosynthesis [2]. In breast cancer,
ntratumoral aromatase is the source for local estrogen
roduction and inhibition of this enzyme is an important
pproach for reducing tumor growth. Tamoxifen, the most
ell-known SERM, has been considered the gold standard
f endocrine therapy in hormone-dependent breast cancer.
owadays, it is being taken over by aromatase inhibitors (AIs)
∗ Corresponding author. Tel.: +351 239859992; fax: +351 239827126.
E-mail address: froleira@ff.uc.pt (F.M.F. Roleira).
039-128X/$ – see front matter © 2008 Elsevier Inc. All rights reserved.
oi:10.1016/j.steroids.2008.07.001in postmenopausal women, due to their superior efficacy
and favorable safety profile [3–6]. The potent and selective
third-generation AIs are being used as endocrine therapy
in postmenopausal patients failing anti-estrogen therapy
alone or multiple hormonal therapies. There are two classes
of AIs, steroidal and nonsteroidal compounds [7–9], which
cause potent estrogen suppression [5,10]. The non-steroidal
AIs are mostly azole type compounds such as the clinically
used anastrazole and letrozole, which compete with the
substrate for binding to the enzyme active site. Steroidal AIs,substrate androstenedione and are converted by the enzyme
in reactive intermediates, which bind irreversibly to the
enzyme active site, resulting in inactivation of aromatase.
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3 4,5Fig. 1 – Steroidal aromatase inhibitors.
Despite the success of the third-generation steroidal and non-
steroidal AIs, they still have some major side effects, such
as the increase of bone loss. For this reason, it is important
to search for other potent and specific molecules with lower
side effects. Moreover, understanding the interactions of new
inhibitors with aromatase lead to new important information
for quantitative structure–activity relationships (QSAR) that
might help to elucidate the 3D structure of the enzyme. The
present study may contribute for these goals.
Recently, a new series of steroids obtained from modifi-
cations in the A- and D-rings of the aromatase substrate,
androstenedione, were designed, synthesized and evaluated
for aromatase inhibitory activity by our group [11]. In that
work, we have studied three main structural features con-
sidered important for the drug–enzyme interaction, namely
the planarity of the A-ring, the 5-stereochemistry and the
integrity of the cyclopentanone D-ring. In the present work,
we have specially focused on the effect of some refined
modifications in the original C-17 carbonyl group in the D-
ring of 5-androst-3-enes and 3,4-epoxy-5-androstanes in
enzyme inhibition. In fact, some authors pointed out that
modifications on C-17 carbonyl group, such as reduction to
a 17-hydroxyl group, or deoxygenation to form a methy-
lene group in analogs of androsta-1,4-diene-3,17-dione causes
only modest decreases in apparent affinity to aromatase
[12]. On the other hand, other authors referred that a 17-
carbonyl group is necessary for a tight binding to aromatase
of the 3-deoxyandrost-4-ene steroid analogs [13].We are inter-
ested to know whether the substitution of the C-17 carbonyl
group in 5-androst-3-enes and 3,4-epoxy-5-androstanes
can affect their aromatase inhibitory activity. For this rea-
son, two steroids, the 5-androst-3-en-17-one 3a and the
3,4-epoxy-5-androstan-17-one 4a (Scheme 1), that have
previously shown to be potent aromatase inhibitors in pla-
cental microsomes [11], are used as lead compounds. From
them, two series of C-17 derivatives bearing hydroxyl (3b,
4b), acetyl (3c, 4c) and hydroxyimine groups (3d, 4d), were
synthesized and their aromatase inhibitory activity evalu-
ated.
2. Experimental
2.1. ChemistryMelting points (Mps) were determined on a Reichert Ther-
mopan hot block apparatus and were not corrected. IR spectra
were recorded on a Jasco 420FT/IR Spectrometer. The 1H NMR
spectra were recorded at 500MHz, on a Varian Unity 500 and0 8 ) 1409–1415
at 300MHz on a Bruker-AC 300 spectrometers. The 13C NMR
spectra were recorded at 125MHz on a Varian Unity 500 and at
75.6MHz on a Bruker-AC 300 spectrometers. Chemical shifts
were recorded in ı values in parts per million (ppm) downfield
from tetramethylsilane as an internal standard. All J-values
are given in Hz. Mass spectra EIMS and ESI were obtained with
mass spectrometers VG AutoSpecQ EI and QTOF2 Micromass
UK. Analytical samples for physicochemical and biological
assays were obtained by column chromatography (silica gel
60 with petroleum ether 40–60 ◦C and ethyl acetate mix-
tures). Reagents and solvents were used as obtained from the
suppliers without further purification. Yields have not been
optimized.
Compound 2 was prepared by Jones oxidation of testos-
terone [14]. Compounds 3a and 4a were prepared as described
[11].
2.2. 5˛-Androst-3-en-17ˇ-ol (3b)
To a solution of 5-androst-3-en-17-one 3a (0.4 g, 1.47mmol)
in methanol (40ml), sodium borohydride (0.2 g, 5.2mmol) was
added and the reaction mixture was stirred at room temper-
ature (23 ◦C). A white precipitate was formed after 15–20min
of stirring and after 1h of reaction TLC control showed that
all the starting material has been consumed. The reaction
was thenworked-up bymethanol evaporation followed by dis-
solution of the residue obtained with diethyl ether (150ml).
The organic layer was then washed with water (3×100ml)
dried, over anhydrousMgSO4, filtered and concentrated todry-
ness giving the pure compound 3b as a white solid (0.359 g,
89% yield). Mp(cyclohexane) 147–150 ◦C (lit [15] 147–150 ◦C); IR
max (KBr) cm−1: 3215 (O H), 3013 ( C H); 1H NMR (300MHz,
DMSO-d6) ı: 0.63 (3H, s, 18-H3), 0.73 (3H, s, 19-H3), 3.42 (1H,
ddd, J17,16 =8.5, J17,16 =8.5, J17,17OH =4.7, 17-H), 4.43 (1H,
d, J17,17OH =4.7, 17-OH), 5.25 (1H, ddd, J4,3 = 9.7, J4,5 =4.5,
J4,2 =2.5, 4-H), 5.52 (1H, ddd, J3,4 = 9.7, J3,2 =6.3, J3,2 =3.1, 3-H);
13C NMR (75.6MHz, DMSO-d6) ı: 11.4 (C-19), 11.7 (C-18), 20.3,
23.0, 23.1, 26.9, 29.8, 31.2, 33.6, 34.5, 35.2, 36.6, 42.7, 45.4 (C-5),
50.6, 53.0, 80.0 (C-17), 125.2 (C-3), 131.1 (C-4); EIMS m/z 274 (M+,
85%).
2.3. 3˛,4˛-Epoxy-5˛-androstan-17ˇ-ol (4b)
To a solution of 5-androst-3-en-17-ol 3b (300mg, 1.09mmol)
in methylene chloride (5.0ml), a solution of performic acid
(0.15ml of HCOOH 98–100% and 0.4ml of H2O2 35%) was
added and the reaction mixture was stirred overnight until
total transformation of the starting material. The reaction
was worked-up by addition of methylene chloride (150ml)
and the organic layer was washed with 10% NaHCO3 (100ml)
followed by water (4×100ml). After drying the organic layer
over anhydrous MgSO4, filtration and solvent evaporation to
dryness gave the pure 4b as a white solid (293mg, 93%).
Mp(ethylacetate/n-hexane) 151–153 ◦C; IR max (KBr) cm−1: 3303
(O H); 1H NMR (300MHz, DMSO-d6) ı: 0.61 (3H, s, 18-H3),
0.72 (3H, s, 19-H ), 2.59 (1H, d, J =3.8, 4-H), 3.08 (1H,
dd, J3,2 =3.0, J3,2 =3.0, 3-H), 3.41 (1H, ddd, J17,16 =8.1,
J17,16 =8.1, J17,17OH =4.5, 17-H), 4.42 (1H, d, J17,17OH =4.5,
17-OH); 13C NMR (75.6MHz, DMSO-d6) ı: 11.4 (C-18), 13.1 (C-
19), 20.5, 20.9, 23.0, 26.2, 29.8, 30.1, 31.1, 33.7, 35.0, 36.5, 42.6,
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Scheme 1 – Synthesis of aromatase inhibitors from testosterone. Reagents and conditions: (i) CrO3, H2SO4, acetone, RT,
5min (98%); (ii) CH3CO2H, Zn dust, 118 ◦C, 15min (60%); (iii) H2O2, HCO2H, dichloromethane, RT, overnight (92–96%); (iv)
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6.5, 50.4, 51.0, 52.3 (C-4), 54.6 (C-3), 80.0 (C-17); EIMS m/z 290
M+, 100%).
.4. 5˛-Androst-3-en-17ˇ-yl acetate (3c)
o a solution of 5-androst-3-en-17-ol 3b (122.5mg,
.45mmol) in dry pyridine (3.0ml), acetic anhydride (0.5ml,
.29mmol) was added and the reaction was stirred overnight
t room temperature until all the starting material has been
onsumed. Methylene chloride (100ml) was added and the
rganic layer was washed with 10% NaHCO3 (2×100ml), 10%
Cl (2×100ml) and water (2×100ml), dried over anhydrous
gSO4, filtered and concentrated to dryness, giving 134.9mg
95%) of the pure 3c as a white solid. Mp(ethanol) 116–119 ◦C
lit [15] 116–118 ◦C); IR max (KBr) cm−1: 3015 ( C H), 1733
C O); 1H NMR (300MHz, CDCl3) ı: 0.77 (3H, s, 18-H3)*, 0.79
3H, s, 19-H3)*, 2.03 (3H, s, CH3COO), 4.59 (1H, dd, J17,16 =7.9,
17,16 =7.9, 17-H), 5.27 (1H, ddd, J4,3 = 9.8, J4,5 =4.5, J4,2 =2.5,
-H), 5.54 (1H, ddd, J3,4 = 9.8, J3,2 =6.3, J3,2 =3.2, 3-H); 13C NMR
75.6MHz, DMSO-d6) ı: 11.8 (C-19)**, 12.2 (C-18)**, 20.5, 21.1,
3.4, 23.5, 27.2, 27.5, 31.5, 34.1, 34.9, 35.3, 36.9, 42.7, 45.8 (C-5),
0.7, 53.3, 82.9 (C-17), 125.4 (C-3), 131.2 (C-4), 171.2 (C O); EIMS
/z 316 (M+, 100%).
(*), (**) Signals may be interchangeable.ight (95%); (vi) NH2OH.HCl, CH3CO2Na·3H2O, methanol,
2.5. 3˛,4˛-Epoxy-5˛-androstan-17ˇ-yl acetate (4c)
To a solution of 5-androst-3-en-17-yl acetate 3c (308mg,
0.97mmol) in methylene chloride (5.0ml), a solution of per-
formic acid (0.15ml ofHCOOH98–100%and0.4ml ofH2O2 35%)
was added and the reaction stirred overnight until complete
transformation of the starting material. Methylene chloride
(150ml) was added and the organic layer was washed with
10% NaHCO3 (2×100ml), water (4×100ml) and dried over
anhydrous MgSO4. After filtration and solvent evaporation to
dryness, 296mg (92%) of the pure compound 4c was obtained
as a white solid. Mp(ethylacetate/n-hexane) 188–190 ◦C; IR max (KBr)
cm−1: 1732 (C O); 1H NMR (300MHz, CDCl3) ı: 0.77 (3H, s, 18-
H3)*, 0.78 (3H, s, 19-H3)*, 2.03 (3H, s, CH3COO), 2.69 (1H, d,
J4,5 =3.9, 4-H), 3.16 (1H, dd, J3,2 =3.0, J3,2 =3.0, 3-H), 4.58
(1H, dd, J17,16 =9.0, J17,16 =7.8, 17-H); 13C NMR (75.6MHz,
DMSO-d6) ı: 12.1 (C-19), 13.4 (C-18), 20.7, 21.2, 21.3, 23.4, 26.6,
27.5, 30.4, 31.4, 34.1, 35.1, 36.8, 42.6, 46.7, 50.5, 52.1** 52.5 (C-4)**,
55.8 (C-3), 82.7 (C-17); 171.2 (C O); EIMS m/z 332 (M+, 87%).
(*), (**) Signals may be interchangeable.2.6. 5˛-Androst-3-en-17-one oxime (3d)
To a solution of 5-androst-3-en-17-one 3a (150mg,
0.55mmol) inmethanol (7.0ml), hydroxylaminehydrochloride
( 2 0
performic acid yielded the epoxide derivative 4a, 4b and
4c in 96%, 93% and 92%, respectively. Reaction of 3a and
4a with hydroxylamine hydrochloride and sodium acetate
in methanol gave the oxime derivatives 3d and 4d with,1412 stero ids 7 3
(49.2mg, 0.7mmol) and CH3COONa·3H2O (90mg, 0.66mmol)
were added. The reaction was stirred at 40 ◦C for 5h until
all the starting material has been consumed. After water
addition (50ml), the methanol was evaporated and the aque-
ous phase was extracted with methylene chloride (100ml).
The organic layer was then washed with NaHCO3 10%
(2×50ml), water (3×100ml), dried over MgSO4, filtered and
evaporated to dryness yielding 133.7mg (84%) of compound
3d. Mp(cyclohexane or petroleum ether 40–60◦C) 159–161 ◦C; IR max
(KBr) cm−1: 3281 (O H), 3013 ( C H); 1H NMR (300MHz,
DMSO-d6) ı: 0.75 (3H, s, 19-H3), 0.82 (3H, s, 18-H3), 5.27
(1H, ddd, J4,3 = 9.5, J4,5 =4.5, J4,2 =2.5, 4-H), 5.54 (1H, ddd,
J3,4 = 9.5, J3,2 =6.1, J3,2 =3.1, 3-H), 10.04 (1H, s, NOH); 13C NMR
(75.6MHz, DMSO-d6) ı: 11.7 (C-19), 17.3 (C-18), 20.2, 22.7, 23.0,
24.7, 26.8, 31.0, 33.5, 34.3, 34.5, 34.6, 43.3, 45.3 (C-5), 52.9,
53.5, 125.3 (C-3), 131.0 (C-4), 167.9 (C-17); ESI m/z 288.2 (M+H,
100%).
2.7. 3˛,4˛-Epoxy-5˛-androstan-17-one oxime (4d)
To a solution of 3,4-epoxy-5-androstane-17-one 4a
(100mg, 0.35mmol) in methanol (7.0ml), hydroxylamine
hydrochloride (30.3mg, 0.44mmol) and CH3COONa·3H2O
(59.5mg, 0.44mmol) were added. The reaction was stirred at
40 ◦C for 5h until all the starting material has been consumed.
After water addition (50ml) the methanol was evaporated and
the aqueous phase was extracted with methylene chloride
(100ml). The organic layer was then washed with NaHCO3
10% (2×50ml), water (3×100ml), dried over MgSO4, filtered
and evaporated to dryness yielding the pure compound 4d
(60mg, 57%). Mp(ethylacetate/n-hexane) 254–257 ◦C; IR max (KBr)
cm−1: 3389 (O H), 1H NMR (300MHz, DMSO-d6) ı: 0.74 (3H,
s, 19-H3), 0.80 (3H, s, 18-H3), 2.60 (1H, d, J4,3 =4.0, 4-H),
3.09 (1H, dd, J3,4 =4.0, J3,2H = 2.0, 3-H), 10.04 (1H, s, NOH);
13C NMR (75.6MHz, DMSO-d6) ı: 13.1 (C-19), 17.3 (C-18),
20.5, 20.9, 22.7, 24.8, 26.2, 30.0, 31.0, 33.8, 34.2, 34.3, 43.2,
46.5, 51.1, 52.3, 53.3, 54.6, 167.9 (C-17); ESI m/z 304.2 (M+H,
100%).
2.8. Preparation of placental microsomes
Placental microsomes were obtained as described by Yoshida
and Osawa [16], with some modifications. Human placen-
tas, obtained after delivery from a local hospital were placed
in cold 67mM potassium phosphate buffer (pH 7.4) con-
taining 1% KCl. The cotyledon tissue was separated and
homogenized in a Polytron homogenizer with 67mM potas-
sium phosphate buffer (pH 7.4) containing 0.25M sucrose and
0.5mM dithiothreitol (DTT, 1:1, w/v). The homogenate was
centrifuged at 5000× g for 30min. The supernatant was cen-
trifuged twice at 20,000× g for 30min and at 54,000× g for
45min to yield a microsomal pellet. The microsomes were
washed and ressuspended in 67mM potassium phosphate
buffer (pH 7.4) containing 0.25M sucrose, 20% glycerol, and
0.5mM DTT and stored at −80 ◦C. All procedures were carried
out at 0–5 ◦C. Protein content was estimated by the Bio-Rad
protein assay (Bio-Rad Labs, Munich, Germany) using bovine
serum albumin (BSA) as standard.0 8 ) 1409–1415
2.9. Aromatase assay procedure
Aromatase activitywasmeasured according to Thompsonand
Siiteri [17], and Heidrich et al. [18], by measuring the 3H2O
released from [1-3H] androstenedione, which was purchased
from PerkinElmer Life Sciences (Boston, MA, USA), during the
aromatization process. All tested compounds were dissolved
in DMSO and diluted in 67mM potassium phosphate buffer
(pH 7.4). Briefly, for the screening assay, the reaction mixture
(1ml) contained 20g of protein of the microsomes, 40nM
of [1-3H]androstenedione (1 Ci) and 2 M of each of the
inhibitors. Aminoglutethymide (AG) and formestane (4-OHA)
were used as control at 2M and 0.5M, respectively. For the
IC50 assay, the reaction mixture (1ml) contained 20 g of pro-
tein, 200nM of [1-3H]androstenedione (1Ci), and different
concentrations of the inhibitors under study in 67mM potas-
sium phosphate (pH 7.4). The aromatase-catalyzed reaction
was initiated by the addition of reduced nicotinamide adenine
dinucleotide phosphate (NADPH, 150M), and incubations
were performed at 37 ◦C for 15min. However, to minimize the
time-dependent loss of the initial aromatization rate, 5min
incubation time was used for the kinetic studies. The reaction
was terminated by addition of 250l of 20% trichloroacetic
acid. The mixture was transferred to microcentrifuge tubes
containing a charcoal–dextran pellet, vortexed and incubated
for 1h. After centrifugation at 14,000× g for 10min, the super-
natants were transferred to new charcoal-dextran pellets,
incubated for 10min and subsequently pelleted by a new
centrifugation cycle. The supernatant containing the tritiated
water product was mixed with a liquid scintillation cocktail
from ICN Radiochemicals (Irvine, CA, USA) and counted in a
liquid scintillation counter (LS-6500, Beckman Coulter, Inc.,
Fullerton, CA). All experiments were carried out in triplicate.
3. Results
3.1. Chemistry
Androstenedione 2 was prepared through oxidation of testos-
terone 1 (Scheme 1) with Jones Reagent and was, as expected,
the only product formed in 98% yield. Clemmensen type
reduction of 2 with zinc powder in acetic acid gave a mix-
ture of 5- and 5-epimers from which the 5-epimer 3a
was isolated by crystallization in 60% yield [11]. Borohy-
dride reduction of 3a in methanol yielded, after work-up,
89% of the steroidal alcohol 3b. Acetylation of 3b with acetic
anhydride in pyridine gave the acetyl derivative 3c in 87%
yield. Treatment of 3a, 3b and 3c, in dichloromethane, withrespectively, 84% and 57% yield. X-ray studies by single
crystal difractometry revealed, unequivocally, the E confor-
mation of the hydroxyimine group of 3d and 4d (unpublished
data).
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Fig. 2 – Aromatase inhibition for steroids 3a–d and 4a–d. Concentrations of 40nM [1-3H]androstenedione, 20g protein
from human placental microsomes, 2M of the compounds and 15min incubation were used. Results were normalized
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.2. Biochemical properties
nhibition of aromatase by 3a, 4a and their respective D-
ing modified derivatives 3b–3d and 4b–4d was evaluated in
lacental microsomes according to the Thompson and Sii-
eri method [17]. A screening assay was performed and the
esults are shown as percentage of inhibition for all com-
ounds at 2M relative to an assay in the absence of the
nhibitor (Fig. 2). To study the range of inhibitory activities for
he compounds under evaluation, the well-known aromatase
nhibitors formestane (4-OHA) and aminoglutethymide (AG),
he first AI approved by FDA, were used as reference
ompounds, showing 97.0%±0.3 and 32.9%±1.8 inhibition,
espectively.
Among the C-17 derivatives of the ring-A epoxide series,
ompound 4a showed to be the most efficient steroid in
nhibiting the enzyme (95.7%±0.3). When a hydroxyl group
ubstituted the C-17 carbonyl group, as in 4b, the capac-
ty to inhibit aromatase decreased to 85.9%±1.3. However, a
ore marked reduction of aromatase inhibitory activity was
bserved (11.7%±0.4) when the acetyl group, replaced the
riginal carbonyl group, as in 4c. The replacement of the car-
onyl group by a hydroxyimine group, as in 4d, resulted in
total incapacity to inhibit aromatase. Compound 3a, the
ead steroid of the ring-A olefin series, showed 94.4%±1.2
Table 1 – In vitro aromatase inhibition
Inhibitor IC50a (M) Kib (M)
3a 0.225±0.012 0.050
4a 0.145±0.002 0.038
3b >30 n.d.
4b 6.5±0.49 4.5
4-OHA 0.042±0.001 n.d.
AG 9.0±0.24 n.d.
The experiments were done in triplicate. The results represent the mean±
n.d.: not determined.
a Concentrations of 200nM [1-3H] androstenedione and 20g of protein
b Apparent inhibition constants (Ki) were obtained by Dixon Plot.
c Inhibition type was based on analysis of Lineweaver–Burk plot.east three independent experiments done in triplicate.
eference substances.
of aromatase inhibition. Substitution of C-17 carbonyl group
by the hydroxyl, acetyl and hydroxyimine groups yielding
compounds 3b, 3c and 3d showed, respectively, 38.9%±4.3,
24.3%±1.6 and no inhibitory capacity.
The IC50 determined for inhibitor 4b was 6.5M, whereas
inhibitor 3b at 30M could not reach 50% of inhibition
(Table 1). Inhibitor 4b showed higher aromatase inhibitory
activity than AG (IC50 = 9.0M), but lower than 4-OHA
(IC50 = 42nM) while 3b was less efficient, in both cases. Inhi-
bition kinetic studies for the most potent inhibitor (4b) were
additionally performed using human placental microsomes.
The type of binding to the active site of aromatase and
the apparent inhibition constant (Ki) were determined. This
steroid 4b revealed to be a competitive inhibitor, as shown in
a Lineweaver–Burk plot in Fig. 3. The Ki, obtained by a Dixon
plot, was 4.5M (Fig. 4).
4. Discussion
According to our previous study [11], steroids 3a and 4a
revealed to be strong aromatase inhibitors with an IC50 of
0.225M and 0.145M and a Ki of 0.050M and 0.038M,
respectively. Androstenedione, the natural substrate of the
enzyme, showed a Km of 0.0575M. These two compounds
Type of inhibitionc Rel affinity (Km/Ki)
Competitive 1.15
Competitive 1.51
n.d. n.d.
Competitive 0.013
n.d. n.d.
n.d. n.d.
S.E. of three different experiments.
from human placental microsomes.
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Fig. 3 – Lineweaver–Burk plot of inhibition of human
placental aromatase by 4b with androstenedione as
substrate. Androstenedione was incubated in a variable
range of concentrations with the microsomal enzyme
preparations and inhibitor 4b at different concentrations (0,
100, 200 and 300nM). Each point represents the mean of
three independent determinations± standard error.
bind the enzyme in a competitive type-manner and with a
slightly higher affinity than androstenedione (respectively,
1.15 and 1.51 times more for inhibitors 3a and 4a) proving
that the C-3 carbonyl group, present in the natural substrate
of the enzyme and in many other aromatase inhibitors, is
not essential for the enzyme–inhibitor interaction and inhibi-
tion. However, the results obtained in the present work show
that unlike C-3 carbonyl, the C-17 carbonyl group present in
the 5-androst-3-ene and 3,4-epoxy-5-androstane deriva-
tives seems to be fundamental to reach maximum aromatase
inhibitory activity. Modification of C-17 carbonyl group of 3a,
such as reduction to a 17-hydroxyl group (3b), dramatically
reduced the capacity of aromatase inhibition. The same type
of chemical transformation performed in inhibitor 4a to give
4b showed only a modest reduction of aromatase inhibitory
Fig. 4 – Dixon plots to determine the apparent inhibition
constant (Ki) for inhibitor 4b. Microsomal proteins (20g)
were incubated with inhibitor 4b (100, 200 and 300nM) and
androstenedione substrate was used at 10nM () and
20nM ().0 8 ) 1409–1415
activity, but a considerable decrease in affinity to aromatase,
from Ki = 0.038M in 4a to Ki = 4.5M in 4b. In fact, the sub-
stitution of a carbonyl group, which is a proton acceptor by a
hydroxyl group, which is a proton donor, could interfere with
the anchoring of the D-ring by the hydrophilic residue of the
active site, which is believed to establish a hydrogen bond
with C-17 carbonyl group. The same behavior was observed by
Numazawa et al. with 3-deoxyandrost-4-ene steroid analogs
[13]. Furthermore, according to a recent model of the active
site of aromatase [19], and a new clamping mechanism of sub-
strate binding to the active site of aromatase [20], the steroidal
D-ring must be anchored by Van der Walls forces through
hydrophobic residues, such as I133 and F134, in the B′–C loop
of aromatase binding pocket. These residues are described
as providing hydrophobic interactions with steroid inhibitors,
stabilizing them in the active site.Webelieve that replacement
of the C-17 carbonyl group in the D-ring of 3a/4a by the more
hydrophilic hydroxyl group, as in 3b/4b, may result in desta-
bilization of the enzyme-compound interaction, decreasing
its inhibitory activity. The better aromatase inhibitory activ-
ity observed for 4b relatively to 3b could be attributed to the
presence of a shared oxygen atom by the C-3 and C-4, in 4b. In
fact, it is accepted that the C-3 carbonyl group of androstene-
dione is involved in its binding to the active site of aromatase
[21,22]. The C-3, C-4 oxygen atom of 4b could play a similar
role of that of C-3 oxygen atom of androstenedione.
The introduction of an acetyl group at C-17 instead of the
carbonyl group, as in 3c and 4c, leads to a more dramatic
reduction of aromatase inhibitory activity. In this case, the
acetyl group is, as the carbonyl group, proton acceptor but
being also a bulky group, may cause steric hindrance at the
enzyme active site, resulting in the observed loss of activity.
Here, the C-3, C-4 oxygen atomof 4c, does not benefit the bind-
ing to aromatase. In this case, the C-17 bulky group seems to
be determinant.
Finally, the substitution of the original carbonyl group by
the hydroxyimine group as in 3d and 4d leads to compounds
with no aromatase inhibitory activity. The hydroxyimine
group is simultaneously proton donor and proton acceptor
and therefore allows the establishment of hydrogen bonds
with the hydrophilic residue of the aromatase active site. Nev-
ertheless, the additional presence of a proton donor group,
which confers hydrophylicity, and the steric hindrance of the
hydroxyimine group may imply conformational conflicts with
the enzyme active site resulting in the complete absence of
aromatase inhibitory activity.
In summary, as long the steroidal five-membered D-
ring is present, a C-17 carbonyl group in 5-androst-3-ene
and 3,4-epoxy-5-androstane series is essential to reach
maximum aromatase inhibitory activity. Additionally, these
compounds should not contain bulky groups in the C-17 posi-
tion in order to have activity. The differences in aromatase
inhibitory activity of 3b and 4b suggest that the binding
geometry of the 3-deoxysteroid (3b) to the active site of aro-
matase would be different from that of the 3,4-epoxysteroid
(4b). This is pointed out by site-directed mutagenesis and
computer-assisted protein-ligand docking studies on 3a and
4a (unpublished results). The presence of an oxygen atom
in the 3,4 position of 4b seems to benefit the binding to the
active site. The results obtained in this study along with those
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lready reported [11–13], particularly those where the C-17
arbonyl group was removed resulting molecules with strong
ctivity [12], lead to the major conclusion that the lack of
ne of the two C-3 or C-17 carbonyl groups in steroidal aro-
atase inhibitors does not affects significantly the aromatase
nhibitory activity but the lack of both affects dramatically the
eferred activity. This statement is reinforced by the fact that
estosterone (1), which has a C-3 carbonyl and C-17 hydroxyl
roups, is as good a substrate for aromatase as is androstene-
ione (2), which has the two C-3 and C-17 carbonyl groups.
t is expected that the results of this study could help in the
uture design of new steroidal aromatase inhibitors as well
s in the establishment of SAR and QSAR for this kind of
ompounds.
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